The Role of Surgical Approach on Residual Limping After Total Hip Arthroplasty (HSS)

November 20, 2023 updated by: Georgios Tsikandylakis, MD PhD, Sahlgrenska University Hospital, Sweden

Abductor Insufficiency After Total Hip Arthroplasty; Risk Factors and Diagnosis

Residual limping after total hip arthroplasty is empirically associated with the use of lateral approach but has been reported in litterature even with the use of posterior approach. The purpose of this clinical trial is to compare the risk of residual limping one year after total hip arthropasty between lateral and posterior approach.

Study Overview

Detailed Description

The use of lateral approach has been empirically associated with increased risk of abductor insufficiency and limping after total hip arthroplasty compared with the posterior approach. However lateral approach remains a widespread technik because it provides a decreased risk of dislocation. In litterature, gluteus medius insufficiency has been reported even when the posterior approach has been used. In the early stage of postperative relhabilitation it is difficult to distinguish between between limping that resolves after abductor training and limping due to abductor injury/avulsion that is resistent to physiotherapy. The purpose of this randomized controlled trial is to compare the risk of persistent limping one year after total hip arthtoplasty between lateral and posterior approach and to identify patient-related risk factors for limping. Moreover it will validate ultra sound (U/S), magnetic resonance imaging (MRI) of the hip and gait analysis as diagnostic tools for early detection of limping that is going to persist one year after total hip arthroplasty.

580 patients will hip osteoarthritis be randomised to receive their total hip arthroplasty through an either lateral of posterior approach and will be followed at one year with physical examination (Trendelenburg sign) and patient.-reported outcome measures. Patients with a positive Trendelenburg sign at 3 months will undergo U/S and MRI examination as well as gait analysis and reassessed at one year with physical examination. The first 40 patients with negative Trendelenburg sign at 3 months will also undergo U/S, MRI and gait analysis. The specificity and sensitivity of U/S, MRI and gait analysis for positiv Trendelenburg sign will be calculated.

Study Type

Interventional

Enrollment (Estimated)

580

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Mölndal, Sweden, 431 80
        • Recruiting
        • Sahlgrenska University Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Primary unilateral osteoarthritis of the hip scheduled for total hip arthroplasty.
  • Ability to understand and write swedish.

Exclusion Criteria:

  • Impaired funktion of the contralateral hip or knees causing limping.
  • Neuromuscular diseases
  • Postoperative leg length discrepancy excceding 1 cm
  • Postoperative discrepancy in femoral offset exceeding 25% of the femoral offset of the contralateral hip.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Lateral approach
290 participants receive their hip prosthesis through a lateral approach. The anterior third of m. gluteus medius along with the corresponding part of m. vastus lateralis are detached from the greater trochanter and the anterior capsule is excised for the exposure of the hip joint. After implant insertion, the gluteus medius is reinserted into the greater trochanter with non-absorbable sutures. Participants are followed at three and 12 months by a physiotherapist.
Total hip arthroplasty performed through a lateral surgical approach (Gammer)
Other Names:
  • Gammer approach
Active Comparator: Posterior approach
290 participants receive their hip prosthesis through a posterior approach. The m. piriformis gemelli and obturator internus are detached from the greater trochanter and the posterior capsule is incised for the exposure of the hip joint. After implant insertion, the posterior capsule as well as m piriformis and the external rotators are reinserted into the greater trochanter with non-absorbable sutures. Participants are followed at three and 12 months by a physiotherapist.
Total hip arthroplasty performed through a posterior surgical approach (Moore)
Other Names:
  • Moore approach

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Trendelenburg sign as binary variable (positive/negative)
Time Frame: At 12 months after intervention
Trendelenburg sign negative if the pelvis remains horisontal while standing only on the operated leg with both arms in anatomical postion. If the pelvismcannot be kept horisontal and tilts towards the kontralateral hip the Trendelenburgs sign is regarded as positive.
At 12 months after intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dislocation
Time Frame: Within 12 months from intervention
Incidens of postoperative dislocation
Within 12 months from intervention
Intraoperative blood loss
Time Frame: Intraoperative
Bleeding during total hip arthroplasty measured in ml
Intraoperative
Periprosthetic infection
Time Frame: Within 12 months from intervention
Incidens of deep surgical wound infection
Within 12 months from intervention
Oxford Hip Score
Time Frame: At 3 months after intervention
Patient-reported hip function measured in a scale of 0-48
At 3 months after intervention
Oxford Hip Score
Time Frame: At 12 months after intervention
Patient-reported hip function measured in a scale of 0-48
At 12 months after intervention
Euroqol 5 dimension 5 level index (EQ5D-5L)
Time Frame: At 3 months after intervention
Patient-reported health-related quality of life measured with the swedish version of euroqol 5 dimension 5 level index 0-1
At 3 months after intervention
Euroqol 5 dimension 5 level index (EQ5D-5L)
Time Frame: At 12 months after intervention
Patient-reported health-related quality of life measured with the swedish version of euroqol 5 dimension 5 level index 0-1
At 12 months after intervention
Euroqol visual analog scale (EQVAS)
Time Frame: At 3 months after intervention
Patient-reported health-related quality of life measured with the euroqol visual analog scale 0-100
At 3 months after intervention
Euroqol visual analog scale (EQVAS)
Time Frame: At 12 months after intervention
Patient-reported health-related quality of life measured with the euroqol visual analog scale 0-100
At 12 months after intervention
University of California Activity Level (UCLA)
Time Frame: At 3 months after intervention
Patient-reported acivity level measured with the University of California Level of Acivity rank scale 0-10
At 3 months after intervention
University of California Activity Level (UCLA)
Time Frame: At 12 months after intervention
Patient-reported acivity level measured with the University of California Level of Acivity rank scale 0-10
At 12 months after intervention
Gluteus medius avulsion in ultrasound
Time Frame: At 3 months after intervention
The proportion avulsed gluteus medius tendon in relation to the whole tendon attachment in a scale of 0 (no avulsion) to 1 (total avulsion). Measured with ultrasound
At 3 months after intervention
Gluteus medius atrophy in Magnetic Resonance Imaging
Time Frame: At 3 months after intervention
The area of gluteus medius muscle in the operated side divided by the area of the gluteus medius muscle in the healthy side as shown in magnetic resonance imaging in a scale of 0 (complete atrophy) to 1 (no atrophy)
At 3 months after intervention
Hip abuction torque
Time Frame: At 3 months after intervention
Hip abuction torque measured in Nm/Kg with gate analysis
At 3 months after intervention
Trendelenburg sign as binary variable (positive/negative)
Time Frame: At 3 months after intervention
Trendelenburg sign negative if the pelvis remains horisontal while standing only on the operated leg with both arms in anatomical postion. If the pelvismcannot be kept horisontal and tilts towards the kontralateral hip the Trendelenburgs sign is regarded as positive.
At 3 months after intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Georgios Tsikandylakis, MD PhD, Sahlgrenska University Hospital, Sweden

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 11, 2022

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

January 15, 2022

First Submitted That Met QC Criteria

January 27, 2022

First Posted (Actual)

January 31, 2022

Study Record Updates

Last Update Posted (Estimated)

November 22, 2023

Last Update Submitted That Met QC Criteria

November 20, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Muscle Weakness

Clinical Trials on Lateral approach

3
Subscribe